Strongbrigde Biopharma 200 Prozent Potential?

Ausgehend vom aktuell Kurs zum KZ von 21USD

www.finanzen.net/analyse/...y-Stifel_Nicolaus__Co__Inc__558835

Pipeline

www.strongbridgebio.com/pipeline/

Strongbridge Biopharma plc Announces Annual General Meeting of Shareholders
GlobeNewswire•February 23, 2018

finance.yahoo.com/news/...plc-announces-annual-123000559.html

Annual General Meeting (AGM) of Shareholders on Tuesday, May 15, 2018 at the offices of Arthur Cox, Ten Earlsfort Terrace, Dublin, Ireland. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 28, 2018.

www.analystratings.com/articles/...uy-rating-from-oppenheimer/

www.analystratings.com/articles/...om-oppenheimer/#more-544448

www.analystratings.com/articles/...strongbridge-biopharma-plc/

www.finanzen.net/nachricht/aktien/...enheimer-analyst-6386702

www.analystratings.com/articles/...gbridge-biopharma-plc-sbbp/

www.analystratings.com/articles/...a-buy-from-h-c-wainwright/

www.zacks.com/stock/news/608278/...=CS-ZC-FT-tale_of_the_tape|yseop_template_4-608278

scheint nur eine Richtung zu kennen! Zumindest aktuell

ich versuche das „aktuell“ auszublenden und mich auf „langfristig“ zu konzentrieren. Die Bewertung ist doch m.E. derzeit eher ein Witz. Vllt gelingt es mir ja, nicht ständig ins Depot zu schauen.  

Von Tief zu Tief....Finger weg! Meine Meinung.

www.finanzen.net/nachricht/aktien/...nen-quartals-vor-8556399

ohne News!

seekingalpha.com/news/...eed_news_all&utm_medium=referral

seekingalpha.com/news/...eed_news_all&utm_medium=referral

www.analystratings.com/articles/...rongbridge-biopharma-sbbp/

seekingalpha.com/article/...bing-the-strongbridge-acquisition

www.pharmatimes.com/news/...n_becomes_available_in_uk_1385622

seekingalpha.com/news/...eed_news_all&utm_medium=referral


www.nasdaq.com/de/market-activity/stocks/xers/real-time

Now what

Cushing's syndrome is rare, but patients display a variety of symptoms usually associated with more common diseases, including elevated blood pressure and blood sugar. As such, it's often misdiagnosed. The availability of a new tablet to treat the disorder could bring enough patients out of the woodwork to drive annual sales above $200 million in a few short years.

Recorlev wasn't the only rare disease drug Xeris acquired from Strongbridge. The company also picked up Keveyis. This is the first and only available treatment approved by the FDA to treat primary periodic paralysis.

During the first nine months of 2021, Keveyis sales rose 33% year over year to $30 million. With the addition of Recorlev to Xeris' product line, the company could feasibly begin generating annual sales above $100 million before the end of 2023.

At recent prices, Xeris Biopharma sports a very modest market cap of just $366 million. That seems extremely cheap for a company with several commercial-stage products. I wouldn't be surprised if this biotech stock shoots through the roof in the new year.

www.fool.com/investing/2021/12/31/...-stock-is-jumping-today/

www.finanzen.net/nachricht/aktien/...hing-s-syndrome-10922686

20 Prozent in einem Monat ist aktuell für einen Biotechtitel nicht schlecht, zumindest wenn es gen Norden geht! Aber nachhaltig sollten die 2,90 / 3 Dollar noch aus dem Weg geräumt werden...

www.nasdaq.com/de/market-activity/stocks/xers/real-time

www.nasdaq.com/articles/...-04-2024%3A-sem-xers-rxrx-omga-nvo